Complete deficiency of complement inhibitor factor I (FI) results in secondary complement deficiency due to uncontrolled spontaneous alternative pathway activation leading to susceptibility to infections. Current genetic examination of two patients with near complete FI deficiency and three patients with no detectable serum FI and also close family members revealed homozygous or compound heterozygous mutations in several domains of FI. These mutations were introduced into recombinant FI and the resulting proteins were purified for functional studies, while transient transfection was used to analyze expression and secretion. The G170V mutation resulted in a protein that was not expressed, whereas the mutations Q232K, C237Y, S250L, I339M and H400L affected secretion. Furthermore, the C237Y and the S250L mutants did not degrade C4b and C3b as efficiently as the WT. The truncated Q336x mutant could be expressed, in vitro, but was not functional because it lacks the serine protease domain. Furthermore, this truncated FI was not detected in serum of the patient. Structural investigations using molecular modeling were performed to predict the potential impact the mutations have on FI structure. This is the first study that investigates, at the functional level, the consequences of molecular defects identified in patients with full FI deficiency.Key words: Complement . Factor I . Human . Immunodeficiency disease
IntroductionThe complement system is a very powerful enzymatic cascade, which is beneficial when activated in response to foreign pathogens, but can be destructive when self-tissues give rise to activation. Therefore, the body is equipped with membrane-bound and soluble complement inhibitors, many of which inhibit complement by acting as cofactors for the serine proteinase factor I (FI). In the presence of cofactors, FI inhibits all pathways of complement by degrading the a 0 -chain of the activated complement components C4b and C3b.Several cases of near complete FI deficiencies have been reported and were found to lead to systemic consumption of C3,
310factor H (FH) and factor B (FB) due to uninhibited activation of the alternative pathway. Because of this consumption, opsonization with C3b cannot occur and patients are much more susceptible to recurrent pyogenic infections, such as otitis media, pneumonia and meningitis [1][2][3][4]. There have also been reports of FI-deficient patients who suffer from glomerulonephritis [5] or systemic lupus erythematosus (SLE) [6]. To date, only three studies have identified a molecular defect in FI at the DNA level in patients with a full FI deficiency [7][8][9]. The remainder of the literature comprises reports of clinical presentation [1-6, 10, 11]. The mutant FI proteins in question have not yet been expressed in a recombinant form and therefore there is no information available concerning the effects of these mutations on FI secretion and function. Mutations in FI have also been identified in atypical hemolytic uremic syndrome (aHUS) patients, where they always occur i...